AMG Affiliate Sells $49.3 Mionionis Stake, Cuts Position by 48%
AMG affiliate Tweedy Browne reduced its Ionis Pharmaceuticals stake by 48%, selling $49.3 million in shares to shrink the position to $52.7 million in the first quarter. Ionis dropped from the fund’s second-largest holding to fifth after the rebalancing, as cash was reallocated into other healthcare names.
1. Fund Portfolio Adjustment
In its latest quarterly filing, Tweedy Browne—a subsidiary of AMG—trimmed its holding in Ionis Pharmaceuticals by 48%, divesting $49.3 million of shares. The move reduced the position from $102 million at year-end to $52.7 million by March 31.
2. Impact on Holding Rankings
Following the sale, Ionis Pharmaceuticals fell from the fund’s second-largest stake to fifth-largest, reflecting a strategic shift in sector weightings. The freed capital was redeployed into other healthcare and industrial names within the portfolio.
3. Strategic Rationale
Tweedy Browne cited valuation discipline and profit‐taking as reasons for the cut, pointing to stretched multiples in biotech stocks. Management indicated the sale aligns with a broader effort to rebalance risk exposure across growth and value segments.